Center for Breakthrough Medicines (CBM), a contract development and manufacturing organization (CDMO) dedicated to addressing critical challenges associated with the commercialization of cell and gene therapies, has signed an agreement with Asimov, a Boston-based mammalian synthetic biology company, to license Asimov’s clonal HEK293 suspension cell line for the production of viral vectors.   HEK293 cell lines are the industry standard for producing therapeutic viral vectors, the most wid...